Integrin-linked kinase 1: role in hormonal cancer progression.
Integrin-linked kinase 1: role in hormonal cancer progression.
复制标题
DOI：
10.2741/s187
复制
发表时间：
2011-01-01
期刊：
影响因子：
--
通讯作者：
Vadlamudi RK
中科院分区：
文献类型：
--
作者：
Cortez V;Nair BC;Chakravarty D;Vadlamudi RK
整合素连接蛋白1(ILK1)是一种丝氨酸/苏氨酸激酶，在细胞生存、迁移和血管生成等多种细胞功能中发挥重要作用。ILK1在许多组织中正常表达，并被生长因子、细胞因子和激素激活。ILK1的表达或功能失调在包括乳腺、卵巢和前列腺在内的几种荷尔蒙肿瘤中被发现。新的证据表明，ILK过表达促进细胞转化、细胞存活、上皮间充质转化(EMT)和荷尔蒙癌细胞的转移，而抑制ILK1则抑制肿瘤的生长和进展。ILK1抑制剂的最新研究进展为阻断ILK1信号通路，抑制荷尔蒙肿瘤的转移和治疗耐药提供了新的机制。这篇综述将集中在了解ILK信号轴在激素性癌症进展中的作用方面的最新进展。
Integrin-linked kinase 1 (ILK1) is a serine/threonine kinase that plays important roles in a variety of cellular functions including cell survival, migration and angiogenesis. ILK1 is normally expressed in numerous tissues and activated by growth factors, cytokines and hormones. Dysregulation of ILK1 expression or function is found in several hormonal tumors including breast, ovary and prostate. Emerging evidence suggests that ILK overexpression promotes cellular transformation, cell survival, epithelial mesenchymal transition (EMT), and metastasis of hormonal cancer cells while inhibition of ILK1 reduces tumor growth and progression. The recent development of ILK1 inhibitors has provided novel mechanisms for blocking ILK1 signaling to curb metastasis and therapy resistance of hormonal tumors. This review will focus on recent advances made towards understanding the role of ILK signaling axis in progression of hormonal cancer.